References
- World Health Organization and Alzheimer's Disease International. Dementia: A Public Health Priority. Geneva: World Health Organization; 2012. [Accessed on 30 April 2014]. Available from http://www.who.int/mental_health/publications/dementia_report_2012/en/
- Factsheet.Dementia.World Health organization.2012 April. [Accessed on 02 May 2014]. Available from: http://www.who.int/mediacentre/factsheets/fs362/en/
- Berchtold NC, Cotman CW. Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s. Neurobiol Aging 1998; 19:173-89; PMID:9661992; http://dx.doi.org/10.1016/S0197-4580(98)00052-9
- Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007; 3:186-91; PMID:19595937; http://dx.doi.org/10.1016/j.jalz.2007.04.381
- Mölsä PK, Marttila RJ, Rinne UK. Survival and cause of death in Alzheimer's disease and multi-infarct dementia. Acta Neurol Scand 1986; 74:103-7; PMID:3776457; http://dx.doi.org/10.1111/j.1600-0404.1986.tb04634.x
- Mölsä PK, Marttila RJ, Rinne UK. Long-term survival and predictors of mortality in Alzheimer's disease and multi-infarct dementia. Acta Neurol Scand 1995; 91:159-64; PMID:7793228; http://dx.doi.org/10.1111/j.1600-0404.1995.tb00426.x
- Pohanka M. Cholinesterases, a target of pharmacology and toxicology. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011; 155:219-29; PMID:22286807
- Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimer's & Dementia. 2013 Mar 9(2).208-45. [Accessed on 01st May 2014]. Available from: http://www.sciencedirect.com/science/article/pii/S1552526013000769
- Alzheimer's Disease International. Policy brief: the global impact of dementia 2013–2050. Alzheimer's Disease International, London. 2013 December. [Accessed on 12th May 2014]. Available from http://www.alz.co.uk/research/G8-policy-brief
- Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc Natl Acad Sci U S A 1996; 93:452-5; PMID:8552659; http://dx.doi.org/10.1073/pnas.93.1.452
- Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400:173-7; PMID:10408445; http://dx.doi.org/10.1038/22124
- Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, et al.; AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64:1553-62; PMID:15883316; http://dx.doi.org/10.1212/01.WNL.0000159740.16984.3C
- Lambracht-Washington D, Rosenberg RN. Advances in the development of vaccines for Alzheimer's disease. Discov Med 2013; 15:319-26; PMID:23725605
- Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 2012; 11:597-604; PMID:22677258; http://dx.doi.org/10.1016/S1474-4422(12)70140-0
- Thomson Reuters. Swiss biotech firm starts new Alzheimer vaccine trial. United States:thomsonreuters;2014 [Accessed on 14 May 2014] Available from: http://www.reuters.com/article/2014/01/09/alzheimers-acimmune-idUSL6N0KJ2QR20140109
- Lemere CA. Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener 2013; 8:36; PMID:24148220; http://dx.doi.org/10.1186/1750-1326-8-36